{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T08:38:59.748047+00:00","company":{"ticker":"ALZN","cik":1677077,"company_name":"Alzamend Neuro, Inc."},"pagination":{"limit":100,"returned":18,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"cc954f391defbd2d8cea46503a5d04f4c90e7329","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2026-03-20T23:59:59+00:00","payload":{"company_response":"Evaluating courses of action; will submit plan to regain compliance","compliance_status":"deficient","cure_deadline":"2026-05-04","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$2.5 million","notice_date":"2026-03-20","notice_type":"deficiency_notice","plan_due_date":"2026-05-04","raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":"$2.2 million","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"March 20, 2026, Alzamend Neuro, Inc., a Delaware corporation\n(the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications staff (the “ Staff ”)\nof the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company’s stockholders’ equity as reported\nin its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 (the “ Form 10-Q ”), did\nnot satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that\na listed company’s stockholders’ equity be at least $2.5 million. As reported on it","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001214659-26-003620","anchor_url":"https://secwatch.observer/filing/0001214659-26-003620#claim-cc954f391defbd2d8cea46503a5d04f4c90e7329","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926003620/0001214659-26-003620-index.htm"},{"fact_type":"material_agreement","fact_key":"8bcd13146f75b64d64199eb3640110eb6863e665","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2026-03-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At-the-Market Issuance Sales Agreement","agreement_type":"atm_program","counterparty":"Ascendiant Capital Markets, LLC","effective_date":"2026-03-06","item_codes_triggered":["1.01"],"value_text":"up to $3.0 million"},"claim":"Alzamend Neuro, Inc. entered into At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $3.0 million (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to $3.0 million (the “ Shares ”) from time to time, through an “at the market offering”","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-26-002932","anchor_url":"https://secwatch.observer/filing/0001214659-26-002932#claim-8bcd13146f75b64d64199eb3640110eb6863e665","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/0001214659-26-002932-index.htm"},{"fact_type":"governance_change","fact_key":"39f03f944dd2e6139f0cae5017fe294d46076293","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2025-10-14T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-10-14","item_codes_triggered":["5.03"],"summary_text":"Filed Certificates of Elimination to remove Series B and Series C preferred stock designations from the Certificate of Incorporation."},"claim":"Alzamend Neuro, Inc.: Filed Certificates of Elimination to remove Series B and Series C preferred stock designations from the Certificate of Incorporation (effective 2025-10-14).","evidence_excerpt":"On October 14, 2025, Alzamend Neuro , Inc., a Delaware corporation (the “ Company ”), filed Certificates of Elimination (collectively, the “ Certificates of Elimination ”) with the Secretary of State of the State of Delaware with respect to the Company’s Series B convertible preferred stock and Series C convertible preferred stock (collectively, the “ Preferred Stock ”), which, effective upon filing, eliminated from the Company’s Certificate of Incorporation, as amended, all matters set forth in the Certificates of Designations for the Preferred Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-25-014950","anchor_url":"https://secwatch.observer/filing/0001214659-25-014950#claim-39f03f944dd2e6139f0cae5017fe294d46076293","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925014950/0001214659-25-014950-index.htm"},{"fact_type":"governance_change","fact_key":"fb78c7e475914015f8dea1c7980e346f743143fc","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2025-07-09T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-09","item_codes_triggered":["5.03"],"summary_text":"Eliminated Series A Preferred Stock Certificate of Designations from Certificate of Incorporation"},"claim":"Alzamend Neuro, Inc.: Eliminated Series A Preferred Stock Certificate of Designations from Certificate of Incorporation (effective 2025-07-09).","evidence_excerpt":"On July 9, 2025, Alzamend Neuro , Inc., a Delaware corporation (the “ Company ”), filed a Certificate of Elimination (the “ Certificate of Elimination ”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A convertible preferred stock (the “ Series A Preferred Stock ”), which, effective upon filing, eliminated from the Company’s Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series A Preferred Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-25-010209","anchor_url":"https://secwatch.observer/filing/0001214659-25-010209#claim-fb78c7e475914015f8dea1c7980e346f743143fc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925010209/0001214659-25-010209-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d4dad20874fa4950db73a0870cfd2abe5358aca6","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-13","outcome":"passed","proposal_text":"Approval of issuance of additional shares of Common Stock upon conversion of Series B Preferred Stock and exercise of warrants pursuant to Securities Purchase Agreement with Ault Lending, LLC to comply with Nasdaq Listing Rule 5635","proposal_type":"other","votes_abstain_text":"49,368","votes_against_text":"208,270","votes_for_text":"2,787,961"},"claim":"Alzamend Neuro, Inc. shareholders approved Approval of issuance of additional shares of Common Stock upon conversion of Series B Preferred Stock and exercise of warrants pursuant to Securities Purchase Agreement with Ault Lending, LLC to comply with Nasdaq Listing Rule 5635 at the 2024-05-13 meeting.","evidence_excerpt":"Proposal Three : Approval, for purposes of complying with Listing Rule 5635 of The Nasdaq Stock Market, LLC, the issuance by the Company of additional shares of Common Stock issuable upon the (i) conversion of up to 6,000 shares of Series B Preferred Stock and (ii) exercise of warrants to purchase up to 6,000,000 shares of Common Stock, for a total purchase price of up to $6,000,000.00, pursuant to the Securities Purchase Agreement dated January 31, 2024 with Ault Lending, LLC. For Against Abstain Broker Non-Votes 2,787,961 208,270 49,368","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008914","anchor_url":"https://secwatch.observer/filing/0001214659-24-008914#claim-d4dad20874fa4950db73a0870cfd2abe5358aca6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008914/0001214659-24-008914-index.htm"},{"fact_type":"governance_change","fact_key":"cb8bb119a9bfd4c9c575e7b26f0f89b1126e8dff","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-10T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-05-09","item_codes_triggered":["5.03"],"summary_text":"Company filed Certificate of Designation for Series A Preferred Stock"},"claim":"Alzamend Neuro, Inc.: Company filed Certificate of Designation for Series A Preferred Stock (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, the Company filed the Certificate designating 3,000 shares of Series A Preferred Stock, with the Secretary of State of the State of Delaware.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001214659-24-008833","anchor_url":"https://secwatch.observer/filing/0001214659-24-008833#claim-cb8bb119a9bfd4c9c575e7b26f0f89b1126e8dff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/0001214659-24-008833-index.htm"},{"fact_type":"material_agreement","fact_key":"952d29b9eaf013a475fc1310b072b6df7aaefb0d","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"a sophisticated investor","effective_date":"2024-05-08","item_codes_triggered":["1.01"],"value_text":"up to $25,000,000.00"},"claim":"Alzamend Neuro, Inc. entered into Securities Purchase Agreement with a sophisticated investor valued at up to $25,000,000.00 (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Agreement ”) with a sophisticated investor (the “ Purchaser ”), pursuant to which the Company agreed to sell to the Purchaser up to 2,500 shares of Series A Convertible Preferred Stock (the “ Series A Preferred Stock ”) and warrants (the “ Warrants ”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) for a total purchase price of up to $25,000,000.00 (the “ Financing ”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008833","anchor_url":"https://secwatch.observer/filing/0001214659-24-008833#claim-952d29b9eaf013a475fc1310b072b6df7aaefb0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008833/0001214659-24-008833-index.htm"},{"fact_type":"material_agreement","fact_key":"2073b1ad1ad14a966063ca39ce54b21788d71897","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"a sophisticated investor","effective_date":"2024-05-08","item_codes_triggered":["1.01"],"value_text":"up to $25,000,000.00"},"claim":"Alzamend Neuro, Inc. entered into Securities Purchase Agreement with a sophisticated investor valued at up to $25,000,000.00 (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Agreement ”) with a sophisticated investor (the “ Purchaser ”), pursuant to which the Company agreed to sell to the Purchaser up to 2,500 shares of Series A Convertible Preferred Stock (the “ Series A Preferred Stock ”) and warrants (the “ Warrants ”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) for a total purchase price of up to $25,000,000.00 (the “ Financing ”) in several tranche closings","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008706","anchor_url":"https://secwatch.observer/filing/0001214659-24-008706#claim-2073b1ad1ad14a966063ca39ce54b21788d71897","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/0001214659-24-008706-index.htm"},{"fact_type":"auditor_change","fact_key":"a572dcfad0439915565a4cdc381d7a82246a9232","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Haskell & White LLP","disagreement_text":null,"effective_date":"2024-05-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Alzamend Neuro, Inc. engaged Haskell & White LLP as its auditor.","evidence_excerpt":"On May 5, 2024, the Audit Committee approved the engagement of Haskell & White LLP","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008699","anchor_url":"https://secwatch.observer/filing/0001214659-24-008699#claim-a572dcfad0439915565a4cdc381d7a82246a9232","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008699/0001214659-24-008699-index.htm"},{"fact_type":"auditor_change","fact_key":"825801c9441efa81276ce7f233778452548c7149","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Baker Tilly US, LLP","disagreement_text":null,"effective_date":"2024-05-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Haskell & White LLP"},"claim":"Alzamend Neuro, Inc. dismissed Baker Tilly US, LLP as its auditor.","evidence_excerpt":"̈ Item 4.01 Changes in Registrant’s Certifying Accountant (a) Dismissal of Previous Independent Registered Public Accounting Firm On\nMay 5, 2024, the Audit Committee (the “ Audit Committee ”) of the Board of Directors of Alzamend Neuro, Inc. (the “ Company ”)\ndismissed Baker Tilly US, LLP (“ Baker Tilly ”) as the Company's independent registered public accounting firm, effective","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008699","anchor_url":"https://secwatch.observer/filing/0001214659-24-008699#claim-825801c9441efa81276ce7f233778452548c7149","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008699/0001214659-24-008699-index.htm"},{"fact_type":"material_agreement","fact_key":"83863f2ca07a32825bbc1ff33708fa533654fcb2","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Agreement","agreement_type":"atm_program","counterparty":"Ascendiant Capital Markets, LLC","effective_date":"2024-05-16","item_codes_triggered":["1.02"],"value_text":null},"claim":"Alzamend Neuro, Inc. terminated Agreement with Ascendiant Capital Markets, LLC (effective 2024-05-16).","evidence_excerpt":"Item 1.02 Termination of a Material Agreement On May 6, 2024, Alzamend Neuro, Inc. (the “ Company ”) provided written notice to Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) of its election to terminate the At-the-Market (“ ATM ”) Issuance Sales Agreement (the “ Agreement” ), dated September 8, 2023, between the Company and the Agent with regards to sales of the Company’s common stock under the Agreement. The Company had sold 1.08 million shares of common stock and raised approximately $1.3 million in gross proceeds, or approximately $1.20 per share, under the ATM. The termination is effective as of May 16, 2024. The material terms of the Agreement are summarized in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 8, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008531","anchor_url":"https://secwatch.observer/filing/0001214659-24-008531#claim-83863f2ca07a32825bbc1ff33708fa533654fcb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008531/0001214659-24-008531-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f9b3d3eaf8a9df06c703fd1a498937ff01ea5e9d","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"Approval of amendment to Certificate of Incorporation to effect a reverse stock split of Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to April 29, 2025","proposal_type":"reverse_split","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"42,325","votes_against":"108,096","votes_for":"4,476,092","votes_withheld":null}]},"claim":"Alzamend Neuro, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to effect a reverse stock split of Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to April 29, 2025 at the 2024-04-30 meeting.","evidence_excerpt":"Proposal Four : Approval of the amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to April 29, 2025, with the exact ratio to be set at a whole number within this range as determined by the Company’s board of directors in its sole discretion. For Against Abstain Broker Non-Votes 4,476,092 108,096 42,325 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008007","anchor_url":"https://secwatch.observer/filing/0001214659-24-008007#claim-f9b3d3eaf8a9df06c703fd1a498937ff01ea5e9d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008007/0001214659-24-008007-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ac144778524b8a99e167bef1ebaf653f6e0894cf","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending April 30, 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"41,600","votes_against":"443,299","votes_for":"5,114,481","votes_withheld":null}]},"claim":"Alzamend Neuro, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending April 30, 2024 at the 2024-04-30 meeting.","evidence_excerpt":"Proposal Two : The ratification of Baker Tilly US, LLP, as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024. For Against Abstain Broker Non-Votes 5,114,481 443,299 41,600 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008007","anchor_url":"https://secwatch.observer/filing/0001214659-24-008007#claim-ac144778524b8a99e167bef1ebaf653f6e0894cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008007/0001214659-24-008007-index.htm"},{"fact_type":"shareholder_vote","fact_key":"86eef455766550c1ec0b74e0990845e055ceefa2","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-01T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-30","outcome":"passed","proposal_text":"Election of eight director nominees","proposal_type":"director_election","results":[{"broker_non_votes":"1,698,070","subject":"Milton C. Ault, III","votes_abstain":"14,002","votes_against":"395,262","votes_for":"3,492,046","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"William B. Horne","votes_abstain":"14,935","votes_against":"400,229","votes_for":"3,486,146","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"Stephan Jackman","votes_abstain":"11,301","votes_against":"175,219","votes_for":"3,714,790","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"Henry C. Nisser","votes_abstain":"14,949","votes_against":"188,030","votes_for":"3,698,330","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"Mark Gustafson","votes_abstain":"14,885","votes_against":"371,660","votes_for":"3,514,765","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"Lynne F. McGrath","votes_abstain":"11,886","votes_against":"164,504","votes_for":"3,724,920","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"Andrew H. Woo","votes_abstain":"11,884","votes_against":"162,827","votes_for":"3,726,599","votes_withheld":null},{"broker_non_votes":"1,698,070","subject":"Jeffrey Oram","votes_abstain":"15,067","votes_against":"365,511","votes_for":"3,520,732","votes_withheld":null}]},"claim":"Alzamend Neuro, Inc. shareholders approved Election of eight director nominees at the 2024-04-30 meeting.","evidence_excerpt":"Proposal One : The election of eight (8) director nominees named by the Company to hold office until the next annual meeting of stockholders. For Against Abstain Broker Non-Votes Milton C. Ault, III 3,492,046 395,262 14,002 1,698,070 William B. Horne 3,486,146 400,229 14,935 1,698,070 Stephan Jackman 3,714,790 175,219 11,301 1,698,070 Henry C. Nisser 3,698,330 188,030, 14,949 1,698,070 Mark Gustafson 3,514,765 371,660 14,885 1,698,070 Lynne F. McGrath 3,724,920 164,504 11,886 1,698,070 Andrew H. Woo 3,726,599 162,827 11,884 1,698,070 Jeffrey Oram 3,520,732 365,511 15,067 1,698,070","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-008007","anchor_url":"https://secwatch.observer/filing/0001214659-24-008007#claim-86eef455766550c1ec0b74e0990845e055ceefa2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008007/0001214659-24-008007-index.htm"},{"fact_type":"debt_financing","fact_key":"c8ee238505ee7f4f6c3faff4357edc094f6042b6","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"counterparty":"an accredited investor","effective_date":"2024-04-29","event":"incurrence","instrument_type":"loan","interest_rate_text":"fifteen percent (15%) per annum","item_codes_triggered":["2.03"],"maturity_text":"May 13, 2024","principal_text":"$310,000"},"claim":"Alzamend Neuro, Inc. incurred loan of $310,000 with an accredited investor at fifteen percent (15%) per annum maturing May 13, 2024.","evidence_excerpt":"Effective April 29, 2024, the Company issued to an accredited investor a term note (the “ Note ”) with a principal face amount of $310,000. The Note bears interest at the rate of fifteen percent (15%) per annum and the Note was issued with an original issuance discount. The maturity date of the Note is May 13, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001214659-24-007877","anchor_url":"https://secwatch.observer/filing/0001214659-24-007877#claim-c8ee238505ee7f4f6c3faff4357edc094f6042b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm"},{"fact_type":"material_agreement","fact_key":"ad3b81327df5c3f45cad26ca0d9e5aeb98824063","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"the Guaranty","agreement_type":"other","counterparty":"Ault Lending","effective_date":"2024-04-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"Alzamend Neuro, Inc. entered into the Guaranty with Ault Lending (effective 2024-04-29).","evidence_excerpt":"Ault Lending Additional Closing On April 29, 2024,\nAlzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”)","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001214659-24-007877","anchor_url":"https://secwatch.observer/filing/0001214659-24-007877#claim-ad3b81327df5c3f45cad26ca0d9e5aeb98824063","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm"},{"fact_type":"material_agreement","fact_key":"3843345b1c9dd69c0dca44d39dba1516814764a4","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"the Note","agreement_type":"credit_facility","counterparty":"an accredited investor","effective_date":"2024-04-29","item_codes_triggered":["1.01"],"value_text":"$310,000"},"claim":"Alzamend Neuro, Inc. entered into the Note with an accredited investor valued at $310,000 (effective 2024-04-29).","evidence_excerpt":"Effective April 29, 2024, the Company issued to an accredited investor a term note (the “ Note ”) with a principal face amount of $310,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-007877","anchor_url":"https://secwatch.observer/filing/0001214659-24-007877#claim-3843345b1c9dd69c0dca44d39dba1516814764a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm"},{"fact_type":"material_agreement","fact_key":"c41730d33038dc9dc17018046e70f32c998899c8","cik":1677077,"ticker":"ALZN","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"the Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Ault Lending, LLC","effective_date":"2024-01-31","item_codes_triggered":["1.01"],"value_text":"$2.1 million"},"claim":"Alzamend Neuro, Inc. entered into the Securities Purchase Agreement with Ault Lending, LLC valued at $2.1 million (effective 2024-01-31).","evidence_excerpt":"lzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”)\nentered into with Ault Lending, LLC, a California limited liability company (“ Ault Lending ”) on January 31, 2024, sold","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001214659-24-007877","anchor_url":"https://secwatch.observer/filing/0001214659-24-007877#claim-c41730d33038dc9dc17018046e70f32c998899c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924007877/0001214659-24-007877-index.htm"}]}